European Pharmaceutical Review

AUGUST 23, 2022

based process (HTA) that will allow the competent EU and national authorities to determine the effectiveness of new or existing health technologies (eg, medicinal products, medical devices, in vitro diagnostic medical devices, medical procedures and measures to prevent, diagnose or treat diseases). About the authors.

95

95

pharmaphorum

AUGUST 12, 2022

It’s the merits that are relevant here. About the author. Unlike batch manufacturing, where drug production is segmented into a series of slow-moving steps, continuous manufacturing relies on a fully integrated process that runs uninterrupted from beginning to end. The case for inshoring is clear.

Packaging 59

Packaging 59

The FDA Law Blog

NOVEMBER 2, 2023

Lewis, Senior Regulatory Device & Biologics Expert — On October 20, 2023, FDA announced the availability of the final guidance authored by CBER titled “Voluntary Consensus Standards Recognition Program for Regenerative Medicine Therapies.” Tobolowsky & Richard A. It finalized a draft guidance published in 2022.

FDA 59

FDA Packaging Documentation Labelling 59

European Pharmaceutical Review

AUGUST 3, 2023

About the author Gareth Morgan is a life sciences partner at multinational law firm Pinsent Masons. EMA Deciding If Donanemab For Alzheimer’s & Three Other Drugs Merit Fast-Tracking. This would be a welcome boost for Alzheimer’s sufferers in Europe. Available from: [link] Sims J, Zimmer J, Evans C , et al. cited 2023Aug].

FDA 52

FDA 52

pharmaphorum

FEBRUARY 15, 2021

You can spend a lot of time debating the merits of Miro, over Google Jamboard, or Microsoft Teams. About the author. Arm yourself with the tools for change. It’s up to any organisation to decide their financial, IT and security processes. What is important though, is getting a tool which can help inspire and gather innovations.

89

89

pharmaphorum

APRIL 22, 2022

If patients are missing out on cost-effective treatments, this is an issue that merits policy attention. About the author. Yet the challenge is that we don’t know whether patients are missing out on cost-effective treatments by the very fact that they don’t get NICE’d.

59

59

The FDA Law Blog

JANUARY 15, 2024

This story goes back to the 2009 Family Smoking Prevention and Tobacco Control Act, which prohibits manufacturers from selling any “new tobacco product” without authorization from FDA. Though a Fifth Circuit merits panel refused, the Court granted rehearing.

FDA 115

FDA Documentation 115

Omnicell

JANUARY 10, 2023

Many 340B provider groups have been calling on HHS to use its existing authority to take immediate enforcement actions against the six drug manufacturers that have refused to offer 340B pricing or have imposed restrictions. Assumptions made in the analysis are not reflective of the position of any entity other than the author(s).

Hospitals 52

Hospitals Insurance Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

MARCH 4, 2021

But with Novartis failing to convince European regulators about the merits of Xiidra last year, and Allergan’s ageing Restasis potentially facing generic competition, there’s a lot to play for and two biotechs are aiming to disrupt the market. Novartis paid Takeda $3.4

FDA 98

FDA Hospitals 98

pharmaphorum

SEPTEMBER 6, 2021

A transition to electronic health records, with opportunities for cost savings and reduced medical errors being the two primary benefits of an electronic-based system, made it hard to argue that a paper-based health record system longer held any merit. About the author.

Medical Records 143

Medical Records Health and Personal Care Stores Data Entry Hospitals 143

pharmaphorum

NOVEMBER 29, 2021

They should drive the discussion beyond just a debate on the merits of a hybrid model, and focus on ways of working that will best support and achieve business priorities. About the author. Our focus needs to be on outcomes and results – it’s not about presenteeism, it’s about productivity. Leaders should be out in front on this.

Communication 92

Communication Packaging Pharmaceutical Companies Pharmaceutical Companies 92

The Physician Pharmacist

SEPTEMBER 26, 2023

I'm also the author of farm data MD and the owner of the physician pharmacist company. Because it's a very recognizable degree, it has holds a lot of merit and status, I think so it's very useful to transition into other fields and use that background. I'm your host, Nathan Gartland.

Medical Schools 52

Medical Schools Communication Hospitals Patient Care 52

pharmaphorum

JUNE 10, 2021

The truth about rising drug prices is more nuanced and merits exploration. About the author. Against this backdrop, there has been substantial public debate about rising drug prices forced on consumers, including the trite notion that pharmaceutical companies are being “greedy” and seeking to price-gouge the public.

Pharmaceutical Companies 105

Pharmaceutical Companies Pharmaceutical Companies Vaccines Documentation 105

The Physician Pharmacist

SEPTEMBER 7, 2023

I'm also the author of PharmD to MD and the owner of the physician pharmacist company. I think this primarily stems from the fact that 100% of medical school, students need to merit a residency position, in contrast to pharmacy, which only about 50% are competing for some of these positions. I'm your host, Nathan Gartland.

Medical Schools 52

Medical Schools Patient Care Independent Pharmacies Insurance 52

ISPE

JANUARY 10, 2023

For critical filters and resins in manufacturing of biological therapeutics, each health authority typically requires approval before final product distribution using alternatives. However, given the continued uncertainty in supply, use of alternative filters or resins may be necessary to ensure continued patient supply of approved biologics.

Packaging 52

Packaging FDA Communication Vaccines 52

The FDA Law Blog

APRIL 29, 2024

DEA states that it has the final authority to reschedule a under the CSA “after considering relevant statutory and regulatory criteria and HHS’ scientific and medical evaluation.” The DEA letter notes that DOJ “is carefully following those procedures as it conducts an administrative review of the scheduling of marijuana.” 21 U.S.C. §

Controlled Substances 59

Controlled Substances FDA 59